EP2742950A4 - Pharmazeutische zusammensetzung mit fibulin-3 protein als wirkstoff zur hemmung des wachstums von krebsstammzellen - Google Patents

Pharmazeutische zusammensetzung mit fibulin-3 protein als wirkstoff zur hemmung des wachstums von krebsstammzellen

Info

Publication number
EP2742950A4
EP2742950A4 EP11870806.4A EP11870806A EP2742950A4 EP 2742950 A4 EP2742950 A4 EP 2742950A4 EP 11870806 A EP11870806 A EP 11870806A EP 2742950 A4 EP2742950 A4 EP 2742950A4
Authority
EP
European Patent Office
Prior art keywords
inhibiting
protein
growth
pharmaceutical composition
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11870806.4A
Other languages
English (en)
French (fr)
Other versions
EP2742950A1 (de
EP2742950B1 (de
Inventor
In-Gyu Kim
Byungchul Shin
Kug Chan Kim
Seo Yeon Kim
Min Jung Kim
So Yong Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Atomic Energy Research Institute KAERI
Original Assignee
Korea Atomic Energy Research Institute KAERI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Atomic Energy Research Institute KAERI filed Critical Korea Atomic Energy Research Institute KAERI
Publication of EP2742950A1 publication Critical patent/EP2742950A1/de
Publication of EP2742950A4 publication Critical patent/EP2742950A4/de
Application granted granted Critical
Publication of EP2742950B1 publication Critical patent/EP2742950B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP11870806.4A 2011-08-09 2011-12-22 Pharmazeutische zusammensetzung mit fibulin-3 protein als wirkstoff zur hemmung des wachstums von krebsstammzellen Active EP2742950B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110079033 2011-08-09
PCT/KR2011/010001 WO2013022157A1 (ko) 2011-08-09 2011-12-22 피불린-3 단백질을 유효성분으로 함유하는 암 줄기세포 성장 억제용 약학적 조성물

Publications (3)

Publication Number Publication Date
EP2742950A1 EP2742950A1 (de) 2014-06-18
EP2742950A4 true EP2742950A4 (de) 2015-04-08
EP2742950B1 EP2742950B1 (de) 2017-03-08

Family

ID=47668646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11870806.4A Active EP2742950B1 (de) 2011-08-09 2011-12-22 Pharmazeutische zusammensetzung mit fibulin-3 protein als wirkstoff zur hemmung des wachstums von krebsstammzellen

Country Status (5)

Country Link
US (1) US20140147423A1 (de)
EP (1) EP2742950B1 (de)
JP (1) JP5717920B2 (de)
KR (1) KR101440487B1 (de)
WO (1) WO2013022157A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676834B2 (en) * 2013-04-02 2017-06-13 Yihong Zhou Fibulin protein variants and corresponding nucleic acid sequences
KR20160047735A (ko) * 2014-10-23 2016-05-03 한국원자력연구원 Ｔｓｐｙｌ５ 발현 또는 활성 억제제를 유효성분으로 함유하는 암줄기세포 성장 및 암 전이 억제용 조성물
KR101635568B1 (ko) * 2014-12-26 2016-07-20 한국원자력연구원 피불린-4 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 폐암 예방 및 치료용 약학적 조성물
KR101746143B1 (ko) 2015-07-08 2017-06-13 한국원자력연구원 Fbln-3 단백질을 유효성분으로 함유하는 췌장암 예방 및 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094054A1 (en) * 2004-11-04 2006-05-04 National Jewish Medical And Research Center Fibulin-3 and uses thereof
US20070220621A1 (en) * 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138297A (ja) * 1993-11-12 1995-05-30 Sumitomo Electric Ind Ltd キメラ分子
EP2227556B1 (de) * 2007-11-19 2014-08-27 Celera Corporation Lungenkrebs-marker und deren verwendungen
KR101325374B1 (ko) * 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094054A1 (en) * 2004-11-04 2006-05-04 National Jewish Medical And Research Center Fibulin-3 and uses thereof
US20070220621A1 (en) * 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EN-LIN SONG ET AL: "EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer", GYNECOLOGIC ONCOLOGY, vol. 121, no. 1, 15 December 2010 (2010-12-15), pages 174 - 180, XP028164676, ISSN: 0090-8258, [retrieved on 20101116], DOI: 10.1016/J.YGYNO.2010.11.004 *
See also references of WO2013022157A1 *

Also Published As

Publication number Publication date
JP2014516053A (ja) 2014-07-07
WO2013022157A1 (ko) 2013-02-14
JP5717920B2 (ja) 2015-05-13
US20140147423A1 (en) 2014-05-29
KR20130019341A (ko) 2013-02-26
EP2742950A1 (de) 2014-06-18
KR101440487B1 (ko) 2014-09-18
EP2742950B1 (de) 2017-03-08

Similar Documents

Publication Publication Date Title
HK1185879A1 (zh) 作為 抑制劑的藥物活性化合物
EP2810558A4 (de) Formulierung mit einer verzögert freigesetzten gelzusammensetzung zur verwendung gegen schädlinge
SG11201406141UA (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
HUP1000069A2 (en) New salts for the preparation of pharmaceutical composition
HK1181753A1 (en) Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them ikk/ tbk-1
EP2823819A4 (de) Pharmazeutische zusammensetzung mit oleanolsäureacetat als wirkstoff zur vorbeugung oder behandlung von tlr-oder il-6-vermittelten erkrankungen
EP2771014A4 (de) Pharmazeutische zusammensetzung zur eliminierung von krebsstammzellen
IL219901A0 (en) Pharmaceutical composiitons for the stimulation of stem cells
EP3037092A4 (de) Zusammensetzung mit einer monoacetyldiglyceridverbindung als wirkstoff zur hemmung von blutkrebs oder metastasen
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EP2687216A4 (de) Pharmazeutische zusammensetzung zur behandlung alterungsbedingter erkrankungen mit einem progerin-expressionshemmer als wirkstoff und screening-verfahren für diesen progerin-expressionshemmer
HK1208188A1 (en) Formulations for the delivery of active ingredients
EP2742950A4 (de) Pharmazeutische zusammensetzung mit fibulin-3 protein als wirkstoff zur hemmung des wachstums von krebsstammzellen
HK1179534A1 (en) Coated preparation containing azosemide as active ingredient
EP2799082A4 (de) Pharmazeutische zusammensetzung zur verhinderung oder behandlung von entzündungserkrankungen oder asthma mit einem lagerstroemia-ovalifolia-extrakt oder einer fraktion davon als wirkstoff
EP2871187A4 (de) Neuartige verbindung oder pharmazeutisch unbedenkliches salz davon und pharmazeutische zusammensetzung damit als wirkstoff
WO2012116254A3 (en) Chrysophaentin analogs that inhibit ftsz protein
IL236466B (en) Pharmaceutical composition for the release of active components
HK1223011A1 (zh) 大葉冬青提取物為有效成分的藥物組合物
PL2704698T3 (pl) Postać leku do kontrolowanego uwalniania substancji czynnych
SI2474529T1 (sl) Kristalne oblike aktivne farmacevtske učinkovine
EP3047849A4 (de) Zusammensetzung zur förderung der differenzierung und proliferation von erythrozyten mit einer monoacetyldiacylglycerinverbindung als wirkstoff
EP2882435B8 (de) Pharmazeutische Formulierungen mit 3-(4-Cinnamyl-L-piperazinyl)aminoderivaten von 3-Formylrifamycin S
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu
SI2497774T1 (sl) Derivati dihidrooksazolobenzodiazepinona, postopki za njihovo pripravo in farmacevtski sestavki, ki te spojine vsebujejo

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150311

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20150305BHEP

Ipc: A61K 38/39 20060101AFI20150305BHEP

Ipc: C07K 14/78 20060101ALI20150305BHEP

Ipc: A61K 38/17 20060101ALI20150305BHEP

17Q First examination report despatched

Effective date: 20151009

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161107

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 872926

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011035834

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170609

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170608

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 872926

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170608

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170710

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170708

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011035834

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

26N No opposition filed

Effective date: 20171211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011035834

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171222

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171222

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171222

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171222

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171222

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20111222

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170308

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230922

Year of fee payment: 13